A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementiaShifu Xiao, Raoli He, Jincai He et al.|Alzheimer s Research & Therapy|2021Cited by 200
Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer’s disease pathogenesisXiaopu Zhou, Marek M. Mesulam, Yu Chen et al.|Proceedings of the National Academy of Sciences|2018Cited by 103
Biomarkers of ageing of humans and non-human primatesZeming Wu, Mingguang He, Jing Qu et al.|Nature Reviews Molecular Cell Biology|2025Cited by 29